P2Y14R antagonist 2 (50, 100 μM for 100μL per mice; rectally administered, daily for 7 days) shows anti-inflammatory activity in mice with colitis[1].
Pharmacokinetic Parameters[1].
| Parameters | dose (mg/kg) | Cmax (ng/mL) | T1/2 (min) | Tmax (min) | AUCall (min*ng/mL) | CL (mL/min/kg) | F (%) |
| iv | 1.0 | - | 21 ± 8.4 | - | 27924 ± 5520 | 133.8 ± 33 | - |
| po | 5.0 | 518.25 ± 196.26 | 177.6 ± 24.6 | 15 | 90744 ± 21613 | 232.2 ± 46.2 | 65.0 |
| Animal Model: | 6-8 weeks, 20-22 g, male C57BL/6 mice (colitis) [1] |
| Dosage: | 50, 100 μM for 100μL per mice |
| Administration: | Rectally administered, daily for 7 days |
| Result: | Alleviated DSS-induced body weight loss, loose stools, rectal bleeding, colon shortening, and elevated spleen weighted index. |
![2-Thiophenecarboxylic acid, 5-[(5-fluoro-2-pyridinyl)oxy]-4-[(4-methylbenzoyl)amino]- Structure](/CAS/20240320/GIF/2989271-65-8.gif)